OXFORD BIODYNAMICS ORD GBP0.001 news, videos and press releases
For more news please use our advanced search feature.
OXFORD BIODYNAMICS ORD GBP0.001 - More news...
OXFORD BIODYNAMICS ORD GBP0.001 - More news...
- Oxford BioDynamics’ EpiSwitch® CRC Blood Test Accurately Detects both Cancer and Polyps
- Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men
- Oxford BioDynamics in San Francisco for the 41st Annual J.P. Morgan Healthcare Conference
- Massachusetts General Hospital Reports Results of Interim Analysis from REFINE-ALS Biomarker Trial by Mitsubishi Tanabe Pharma USA, Utilizing Oxford Biodynamics’ EpiSwitch® Platform for Prognostic Stratification of Fast Progression ALS
- Oxford BioDynamics’s Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK
- Oxford BioDynamics Awarded US FNIH Grant to Apply EpiSwitch® Immune Health Test for Improved Prediction of Patient Response to Immune Checkpoint Inhibitor (ICI) Cancer Therapies
- Oxford BioDynamics' EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs
- Oxford BioDynamics Joins ALS Biomarker Study Sponsored By Mitsubishi Tanabe Pharma America
-
Stock in Focus - Oxford BioDynamics - Mark Johnson
